Rachel Riedesel
Family · Clinton, IANPI 1396269221
Payments from drug & device makers
Across 187 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$428
- Amgen$338
- Novo Nordisk$300
- Exact Sciences$295
- AstraZeneca$282
- Boehringer Ingelheim$261
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,114100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 24 | $428 |
| Amgen | 21 | $338 |
| Novo Nordisk | 19 | $300 |
| Exact Sciences | 17 | $295 |
| AstraZeneca | 17 | $282 |
| Boehringer Ingelheim | 16 | $261 |
| Lilly USA, LLC | 14 | $212 |
| GSK | 11 | $167 |
| AbbVie | 9 | $167 |
| Novartis | 8 | $129 |
| Mylan Specialty L.p. | 6 | $82 |
| Dexcom, Inc. | 4 | $76 |
| Astellas Pharma US Inc | 3 | $47 |
| Insulet Corporation | 1 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| Harmony Biosciences LLC | 1 | $19 |
| Abbott | 1 | $18 |
| Bayer | 1 | $15 |
| Medtronic | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$3,114 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $80,960 |
| MounjaroTirzepatide | 57 | $64,192 |
| OzempicSemaglutide | 54 | $62,799 |
| JardianceEmpagliflozin | 85 | $61,341 |
| XareltoRivaroxaban | 71 | $56,150 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 68 | $49,087 |
| JanuviaSitagliptin Phosphate | 37 | $29,361 |
| LinzessLinaclotide | 46 | $28,862 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $22,928 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,206 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $21,132 |
| FarxigaDapagliflozin Propanediol | 36 | $19,359 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $18,898 |
| OxycontinOxycodone Hcl | 22 | $16,593 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $13,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat, Spiriva Respimat | $261 | $103,492142 claims |
| PfizerEliquis | $428 | $80,96071 claims |
| Novo NordiskOzempic, Rybelsus | $300 | $76,26267 claims |
| Lilly USA, LLCMounjaro | $212 | $64,19257 claims |
| Johnson & JohnsonXarelto | $29 | $56,15071 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $42 | $49,08768 claims |
| AstraZenecaFarxiga, Symbicort, Bevespi Aerosphere | $282 | $39,254105 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $167 | $32,05751 claims |
| AbbVieLinzess | $167 | $28,86246 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $13,10926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.
Other family in Clinton
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.